rosuvastatín/ezetimib teva 20 mg/10 mg
teva b.v., holandsko - rosuvastatín a ezetimib - 31 - hypolipidaemica
rosuvastatín/ezetimib teva 10 mg/10 mg
teva b.v., holandsko - rosuvastatín a ezetimib - 31 - hypolipidaemica
rosuvastatín/ezetimib teva 5 mg/10 mg
teva b.v., holandsko - rosuvastatín a ezetimib - 31 - hypolipidaemica
everio airmaster 50 mikrogramov/100 mikrogramov
zentiva k.s., Česká republika - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica
everio airmaster 50 mikrogramov/250 mikrogramov
zentiva k.s., Česká republika - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica
everio airmaster 50 mikrogramov/500 mikrogramov
zentiva k.s., Česká republika - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica
zercepac
accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastické činidlá - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. pred chemoterapiou musí obsahovať aspoň anthracycline a taxane pokiaľ pacienti sú nevhodné pre tieto liečby. hormonálny receptor pozitívnych pacientov musí tiež zlyhali, hormonálna terapia, pokiaľ pacienti sú nevhodné pre tieto liečby. in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. v kombinácii s docetaxel na liečbu tých pacientov, ktorí boli liečení chemoterapiou, pre svoje metastázy. v kombinácii s inhibítor aromatázy pre liečbu pacientov po menopauze s hormón-receptor pozitívne mbc, ktoré predtým neboli liečení trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). po operácii, chemoterapii (neoadjuvant alebo adjuvantnej) a rádioterapie (ak je to uplatniteľné). nasledujúce adjuvantná chemoterapia s doxorubicin a cyklofosfamidom, v kombinácii s paclitaxel alebo docetaxel. v kombinácii s adjuvantná chemoterapia pozostávajúce z docetaxel a carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. presné a overené skúšobné metódy by mali byť použité.
vak krvný eastern
eastern medikit limited narag merg, delhi, india india -
zátka injekčná eastern
eastern medikit limited narag merg, delhi, india india -
zátka luer eastern
eastern medikit limited narag merg, delhi, india india -